The genetic epidemiology of neurodegenerative disease
Open accessThe DOI matches its Crossref record; 103 of the 106 references it cites were found in a registry or an index.
Abstract
Gene defects play a major role in the pathogenesis of degenerative disorders of the nervous system.In fact, it has been the very knowledge gained from genetic studies that has allowed the elucidation of the molecular mechanisms underlying the etiology and pathogenesis of many neurodegenerative disorders.In this review, we discuss the current status of genetic epidemiology of the most common neurodegenerative diseases: Alzheimer disease, Parkinson disease, Lewy body dementia, frontotemporal dementia, amyotrophic lateral sclerosis, Huntington disease, and prion diseases, with a particular focus on similarities and differences among these syndromes. The complexities of common diseasesFamilial aggregation had been recognized as a prominent characteristic of many neurodegenerative disorders decades before the underlying molecular genetic or biochemical properties were known.It was often the identification of specific, disease-segregating mutations in previously unknown genes that directed the attention to certain proteins and pathways that are now considered crucial in the pathogenesis of these diseases.These include mutations in the β-amyloid (Aβ) precursor protein, causing Alzheimer disease (AD); in α-synuclein, causing Parkinson disease (PD); or in microtubule-associated protein tau, causing frontotemporal dementia (FTD) with parkinsonism.Another feature observed in most common neurodegenerative diseases -as well as in other common disorders -is a dichotomy between familial (rare) and seemingly nonfamilial (common) forms.The latter are also frequently described as "sporadic" or "idiopathic," although there is a growing body of evidence suggesting that a large proportion of these cases are also significantly influenced by genetic factors.These risk genes are likely to be numerous, displaying intricate patterns of interaction with each other as well as with nongenetic variable, and -unlike classical Mendelian ("simplex") disorders -exhibit no simple or single mode of inheritance.Hence, the genetics of these diseases has been labeled "complex."A popular conception regarding the genetic makeup of complex diseases is the "common disease/common variant" (CD/CV) hypothesis (1).According to this theory common disorders are also governed by common DNA variants (such as single nucleotide polymorphisms.These variants significantly increase disease risk but are insufficient to actually cause a specific disorder.Current empirical and theoretical data support this hypothesis, although there remains great uncertainty as to the number of the underlying risk factors and their specific effect sizes.In this context, it is noteworthy that even recent genetic advances in the study of complex diseases such as AD or diabetes likely only represent the most obvi-ous, most extreme cases of the underlying risk spectrum (Figure 1; ref.2).In AD, for instance, rare, fully penetrant autosomal dominant mutations in 3 genes (i.e.APP, PSEN1, and PSEN2) have been shown to cause the disease, while a common, incompletely penetrant susceptibility variant (i.e., ε4 in APOE; see below) significantly increases the risk for AD.The identification of these genes early in the study of AD genetics was possible due to the combination of several favorable circumstances, such as the presence of multiple independent mutations in the same locus and the availability of extended, multigenerational pedigrees for DNA genotyping and sequencing (in the case of PSEN1) or a large attributable fraction to the overall genetic variance, resulting from relatively high allele frequency and pronounced effect size (in the case of APOE).However, identification of disease genes that make smaller overall contributions to the genetic spectrum (because of only few mutational events; e.g., PSEN2), or risk factors with smaller effect sizes (i.e.odds ratios [ORs] ranging between 2 and 3), will require much larger samples and possibly more sensitive and efficient analytic tools to enable consistent detection across study populations (2).Additional, and commonly cited, problems in finding complex disease genes beyond the most obvious are multiple testing, publication bias, and questionable replication (3-5).Multiple testing can be placed under the larger category of "avoidable false positive" findings, which are also caused by testing insufficiently sized samples, using inappropriate matching of cases versus controls, stratifying populations, and choosing inadequate analysis strategies, etc. Publication bias, on the other hand, which indicates the higher a priori likelihood of a positive finding being published as opposed to a negative one, may have been a possible source of serious bias in the early days.However, there is only relatively little empirical evidence that publication bias actually represents a common or significant source of error in current publications investigating the genetics of a number of disorders (e.g., refs.6-12).The sheer number of publications in the AD gene
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Elevated levels of Amyloid-β (Aβ) peptide initiates a cascade of events that ultimately result in Alzheimer’s disease (AD) [1–4].”
From Amyloid-β interrupts canonical Sonic hedgehog signaling by distorting primary cilia structure (2018) · cites this paper as [4]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
MACDONALD, M. (1993) · Cell · doi:10.1016/0092-8674(93)90585-e · Cited by 8,366
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Rosen, D. R., Siddique, T., Patterson, D., Figlewicz, D. A., Sapp, P., Hentati, A., Donaldson, D., Goto, J., O'Regan, J. P., Deng, H.-X., et al. (1993) · Nature · doi:10.1038/362059a0 · Cited by 7,062
Prusiner, S. B. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.23.13363 · Cited by 5,373
Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism
Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y., & Shimizu, N. (1998) · Nature · doi:10.1038/33416 · Cited by 5,227 · cited 4×
“The most frequently involved gene in recessive parkinsonism is parkin (PRKN) on chromosome 6q25 (33, 41), which causes nearly half of all early-onset PD cases.”
BackgroundInfluentialGoate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659 · cited 5×
“In AD, for instance, rare, fully penetrant autosomal dominant mutations in 3 genes (i.e. APP, PSEN1, and PSEN2) have been shown to cause the disease, while a common, incompletely penetrant susceptibility variant (i.e., ε4 in APOE; see below) significantly increases the risk for AD.”
BackgroundInfluentialα-Synuclein Locus Triplication Causes Parkinson's Disease
Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., et al. (2003) · Science · doi:10.1126/science.1090278 · Cited by 4,383
Strittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268 · cited 1×
“AD APP (15) Aβ precursor protein 21q21 Dominant Altered Aβ production (Aβ42/Aβ40 ratio ↑) and aggregation AD APOE (21, 22) Apolipoprotein E 19q13 Risk factor Unknown (Aβ aggregation? lipid metabolism?) AD PSEN1 (16) Presenilin 1 14q24 Dominant Altered Aβ production (Aβ42/Aβ40 ratio ↑) AD PSEN2 (17, 18) Presenilin 2 1q…”
BackgroundCloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995) · Nature · doi:10.1038/375754a0 · Cited by 4,051 · cited 9×
“In AD, for instance, rare, fully penetrant autosomal dominant mutations in 3 genes (i.e. APP, PSEN1, and PSEN2) have been shown to cause the disease, while a common, incompletely penetrant susceptibility variant (i.e., ε4 in APOE; see below) significantly increases the risk for AD.”
BackgroundInfluential
Research works printed but not linked: 1
- [92]Prusiner, S.B. 1998. Prions. Proc. Natl. Acad. Sci. U. S. A. 95 :13363-13383.
Cited by
Items 501–600 of 678
Genetics of Neurodegenerative Diseases
Lill, C. M., Tanzi, R. E., & Bertram, L. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-374947-5.00041-9 · Cited by 3
Self-citationAssociation of AXIN1 With Parkinson’s Disease in a Taiwanese Population
Fang, H.-S., Chao, C., Wang, C., Fan, W., Huang, P.-J., Fung, H., & Wu, Y. (2021) · Journal of Movement Disorders · doi:10.14802/jmd.21073 · Cited by 2
Cojocaru, A., Rotaru-Zăvăleanu, A. D., Călina, D. C., Gheonea, D. I., Osiac, E., Boboc, I. K. Ş., & Mitran, S. I. (2021) · PubMed Central · doi:10.12865/chsj.47.02.17 · Cited by 3
“Genes like APP, PSEN1, PSEN2 [3], TREM2 [4], ApoE [5,6] have been described as the genetic triggers of AD, but they are responsible for a relatively small number of patients that have early onsets AD (before 65 years of age) [3,7].”
BackgroundfMRI in Neurodegenerative Diseases: From Scientific Insights to Clinical Applications
Dickerson, B. C. (2009) · Neuromethods · doi:10.1007/978-1-60327-919-2_22 · Cited by 3
Genetic Causes of Alzheimer’s Disease and the Neuroprotective Role of Melatonin in its Management
Sundram, S., Malviya, R., & Awasthi, R. (2022) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527321666220901125730 · Cited by 2
Cost-effectiveness of a gene sequencing test for Alzheimer’s disease in Ontario
Iragorri, N., Toccalino, D., Mishra, S., Chan, B., Dilliott, A. A., Robinson, J. F., Hegele, R. A., Hancock, R., & The ONDRI Investigators (2022) · Journal of Community Genetics · doi:10.1007/s12687-022-00619-7 · Cited by 2
“Genetics are acknowledged as an important risk factor in the development of AD with approximately 5–10% of cases having an inheritable genetic component (Garcia and Bustos 2018; Guerreiro et al. 2014; Bertram and Tanzi 2005).”
BackgroundDubey, S., Ghosh, R., Dubey, M. J., Das, S., Chakraborty, A. P., Santra, A., Dutta, A., Roy, D., Pandit, A., Roy, B. K., et al. (2023) · Medical Research Archives · doi:10.18103/mra.v11i5.3919 · Cited by 3
“[7-13] Extrapolation of allelic heterogeneity and pleiotropy in the neuropsychiatric continuum provide the best explanation for a family with a history of genetic neurological diseases may have psychiatric ailments or vice versa, considering overlapping clinical features and shared anatomical, pathological, and molecu…”
BackgroundNanomaterials regenerative medicine and tissue engineering
Banerjee, S., Banerjee, S., & Mondal, A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-95134-0.00001-8 · Cited by 2
Sankaramourthy, D., Kavimani, S., Sadras, S. R., & MURALIMOHAN, U. (2021) · International Journal of Pharmaceutical Sciences and Drug Research · doi:10.25004/ijpsdr.2021.130110 · Cited by 2
Etiology and treatment challenges for neurodegenerative disorders
Wankhede, N. L., Kale, M. B., Shende, P. V., Ratne, N., Taksande, B. G., Upaganlawar, A. B., Umekar, M. J., & Magrulkar, S. V. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23841-3.00001-7 · Cited by 9
ŞİZOFRENİ VE BİPOLAR BOZUKLUKLAR İLE ENFEKSİYON HASTALIKLARI ARASINDAKİ İLİŞKİNİN ARAŞTIRILMASI
Önlen, C. (2017) · Mustafa Kemal Üniversitesi Tıp Dergisi · doi:10.17944/mkutfd.376516 · Cited by 2
MicroRNAs in neurodegenerative eye disease
Ramón, A., Romo-García, E., Alvarez-Félix, J. R., Paz-Camacho, S., Meza, E. L., Pujalte, I. V., Mellado, I. O., Barraza, M. L., & Rojo, C. A. (2020) · Advances in Ophthalmology & Visual System · doi:10.15406/aovs.2020.10.00384 · Cited by 2
Goldfein, S. K., & Qualls, C. D. (2005) · Perspectives on Gerontology · doi:10.1044/gero10.2.7 · Cited by 2
Cu2+ Affects Amyloid-\b{eta} (1-42) Aggregation by Increasing Peptide-Peptide Binding ForcesPreprint
Hane, F. T., Tran, G., Attwood, S. J., & Leonenko, Z. (2017) · arXiv (Cornell University) · doi:10.48550/arxiv.1704.08317 · Cited by 2
“Genetic factors [10], metals [5,11], and vascular deficiencies [12] have been found to be associated with AD.”
Espinel, M. D. C. (2014) · UVaDOC UVaDOC University of Valladolid Documentary Repository (University of Valladolid) · doi:10.35376/10324/7752 · Cited by 6
The Genetic Profiles of TIF1 and TIF2 Duplicate Genes
Venturi, V. (2012) · Open Access Victoria University of Wellington | Te Herenga Waka (Figshare) · doi:10.26686/wgtn.16999348.v1 · Cited by 2
Alpha-synuclein-specific regulatory T cells ameliorate Parkinson’s disease progression in micePreprint
Bae, H., Park, S., Yang, H., Go, H., & Kim, H.-S. (2023) · Research Square · doi:10.21203/rs.3.rs-2153516/v2 · Cited by 2
Luo, Y. (2017) · Springer eBooks · doi:10.1007/978-3-319-51671-4_6 · Cited by 1
Silva‐Lucero, M., Rivera‐Osorio, J., Gomez‐Virgilio, L., López-Toledo, G., Luna‐Muñoz, J., Montiel-Sosa, J. F., Soto-Rojas, L. O., Pacheco‐Herrero, M., & Cárdenas‐Aguayo, M. D. C. (2022) · Diagnostics · doi:10.3390/diagnostics12051165 · Cited by 3
Two cellular models for analyzing mitochondrial heteroplasmy
Hu, Y., Jiang, L., Liu, W., & Zhao, X. (2025) · Exploration of neuroscience · doi:10.37349/en.2025.100669 · Cited by 1
Multi-omics and biomarker discoveries in Alzheimer's disease
Khan, I. A. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-13595-8.00006-4 · Cited by 2
DNA: detecting early signs of neurodegenerative diseases through activity and sleep analysis
Attaullah, H., Sanaullah, S., Peters, A., Ahmed, Q. A., Baudisch, J., & Jungeblut, T. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1617758 · Cited by 2
Agarwal, U., Paliwal, S., Yadav, V., Pannu, A. S., Tonk, R. K., & Verma, S. K. (2025) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/0118715273402657250905055635 · Cited by 2
Matthews, B. R., & Miller, B. L. (2009) · Cambridge University Press eBooks · doi:10.1017/cbo9780511581410.005 · Cited by 1
Non-coding RNA in Neurodegeneration
Ciccodicola, A., Ambrosio, M. R., Scarpato, M., & Costa, V. (2012) · Current Geriatrics Reports · doi:10.1007/s13670-012-0023-4 · Cited by 1
“In addition, hereditary forms of Prion diseases, such as Creutzfeld-Jacob disease, have been associated to mutations in the gene encoding PrP (PRNP) [5].”
BackgroundF4‐01‐02: Alzheimer's disease genetics: Current status and future perspectives
Bertram, L. (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.05.507 · Cited by 1
“Similar to many other adult-onset disorders, Alzheimer’s disease (AD) shows a genetic dichotomy of cases with Mendelian inheritance (‘‘simplex AD’’) versus cases governed by an array of diVerent genetic and nongenetic risk factors (‘‘complex AD’’; Bertram and Tanzi, 2005; Tanzi, 1999).”
Self-citationHow does the genetic assassin select its neuronal target?
Stevens, J. C., Fisher, E., & Mead, S. (2011) · Mammalian Genome · doi:10.1007/s00335-011-9319-5 · Cited by 1
“Now all common neurodegenerative diseases have at least one strong genetic cause, and typically multiple causal loci (Bertram and Tanzi 2005; Hardy 2005).”
BackgroundGenetic and Environmental Factors in Neurodegenerative Diseases
Coppedè, F., & Migliore, L. (2007) · Elsevier eBooks · doi:10.1016/b978-044452809-4/50144-7 · Cited by 2
Poddar, M. K., & Chakraborty, A. (2019) · Acta Scientifci Nutritional Health · doi:10.31080/asnh.2019.03.0458
Clinical and Pre-Clinical Evidence for Enteric α-Synuclein Involvement in Parkinson's Disease
Kochman, E. M., Akhtar, K., Ali, A., & Shin Damian, S. (2021) · International Journal of Neurodegenerative Disorders · doi:10.23937/2643-4539/1710019 · Cited by 5
Pharmacogenomics and Personalized Medicine in Alzheimer’s Disease
Archer, T., & Johansson, B. E. A. (2013) · Springer eBooks · doi:10.1007/978-81-322-1184-6_15 · Cited by 1
Mansour, M. A. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.87536 · Cited by 2
Alzheimer’s Disease and Frontotemporal Lobar Degeneration: Mouse Models
Ittner, L. M., Lee, W. S., Stefanoska, K., Asih, P. R., & Ke, Y. D. (2018) · Springer eBooks · doi:10.1007/978-3-319-72938-1_10 · Cited by 1
Methylation of MAPT Gene in Neurodegenerative Synucleinopathies
Iakovenko, E. V., Abramycheva, N. Y., Fedotova, E. Y., & Illarioshkin, S. N. (2022) · Russian Journal of Genetics · doi:10.1134/s1022795422050118 · Cited by 1
“The progression of the disease averaged four years [3; 7].”
BackgroundPlant-Derived Bioactive Compounds: Promising Prospective Uses in the Chronic Inflammation
Pushpalatha, D. S. S. P. S., Kumaraswamy, S., Selvaraj, G. K., Narayanaswamy, R., Vasantha‐Srinivasan, P., Sivakumar, T., & Kesavan, A. (2023) · Advances in medical diagnosis, treatment, and care (AMDTC) book series · doi:10.4018/979-8-3693-0703-8.ch011 · Cited by 2
McGlynn, C., Dermawan, D., & Canonizado, G. M. (2024) · Brain Science Advances · doi:10.26599/bsa.2023.9050026 · Cited by 1
“The family of neurodegenerative diseases presents in a highly variable and individual manner [97], and some people suffering from them will undoubtedly be more responsive to the individual therapeutic components of the Neuron Foundry Mach 8 .”
Ameliorative Effect of Nebivolol in Parkinson’s disease
Nade, V. S., & Pagare, P. S. (2014) · HAL · Cited by 1
The Genetic and environmental risk Factors of Alzheimer’s disease
Verma, J. Y. A. P. A. K. (2018) · International Journal of Aging Research · doi:10.28933/ijoar-2018-07-2401 · Cited by 1
Cerebellar cortex сhanges in posterity of female rats receiving PgE2 for induction of parturition.
Grigorieva, E., & Mamay, I. Y. (2018) · Morphologia · doi:10.26641/1997-9665.2018.3.56-60 · Cited by 1
Harrison, A. T., McAllister, T. W., McCrea, M., Broglio, S. P., Moore, R. D., Anderson, S. A., Benjamin, H. J., Buckley, T. A., Chisman, S. P. D., Clugston, J. R., et al. (2020) · Journal of Neurotrauma · doi:10.1089/neu.2020.7386 · Cited by 1
Kumar, S., Maurya, H., Sandeep Sandeep, S., Sen, S., & Chakraborty, R. (2021) · Indian Journal of Pharmaceutical Education and Research · doi:10.5530/ijper.55.1.15 · Cited by 1
Ashok, C., & Anil, D. (2022) · Journal of Neurodegenerative Disorders · doi:10.36959/459/608 · Cited by 1
Mechanisms involved in prevention of dementia and promotion of healthy aging by resveratrol
Tiwari, B. K., & Pandey, K. B. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-90581-7.00007-4 · Cited by 1
Development of Cinnarizine Liposome Technology
Polkovnikova, Y. A. (2022) · Health Food & Biotechnology · doi:10.36107/hfb.2022.i4.s153 · Cited by 1
The aging synapse: Synaptic proteome changes in mouse models of aging
Végh, M. J. (2012) · Digital Academic REpository of VU University Amsterdam (Vrije Universiteit Amsterdam) · Cited by 1
Regulación de la plasticidad astrocitaria por ibuprofeno y FGF2
Lichtenstein, M. P. (2011) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) · Cited by 1
Single Molecule Force Spectroscopy Investigations of Amyloid-β Aggregation
Hane, F. T. (2013) · UWSpace (University of Waterloo) · Cited by 2
Möglichkeiten und Konsequenzen genetischen Diagnostik im klinischen Alltag
Salili, A. Y. (2006) · Swiss Medical Forum ‒ Schweizerisches Medizin-Forum · doi:10.4414/smf.2006.05788 · Cited by 1
Gene-Environment Interactions in Neurodegenerative Diseases
Hannan, A. J. (2011) · Elsevier eBooks · doi:10.1016/b978-0-444-52272-6.00076-3 · Cited by 1
Elmabruk, A. S. M. (2018) · Human Biology · Cited by 1
The effects of midlife diet on late-life cognition : an epidemiological approach
Eskelinen, M. H. (2014) · UEF eRepo (University of Eastern Finland) · Cited by 7
Bureau, S. C. (2022) · Carleton University's Institutional Repository (MacOdrum Library, Carleton University) · doi:10.22215/etd/2022-14889 · Cited by 1
Mattson, M. P. (2012) · Springer eBooks · doi:10.1007/978-3-540-29807-6_145 · Cited by 1
Acupuncture for Parkinson's Disease
Wang, L., Xie, Y., Zhang, S., & Wu, T. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006236 · Cited by 1
Alzheimer’s Disease and Frontotemporal Lobar Degeneration: Mouse Models
van Eersel, J., Delerue, F., Ittner, L. M., & Ke, Y. D. (2014) · Springer eBooks · doi:10.1007/978-1-4471-6380-0_8
Fenney, A. (2007) · Archipel (Université du Québec à Montréal)
Optimization of Neuron cells Maturation and Differentiation
Chotimah, C., Rahayu, M., Ciptadi, G., & Biologi, J. (2014) · Biotropika Journal of Tropical Biology
Insulin Receptor and the Pathophysiology of Alzheimer Disease
Zemva, J., & Schubert, M. (2013) · Wiley eBooks · doi:10.1002/9781118395318.ch2
Investigations in Old Age Psychiatry
Merve, S., & Baldwin, R. (2010) · Wiley eBooks · doi:10.1002/9780470669600.ch23
Molecular Neuroimaging of the Dementias
Dickerson, B. C. (2011) · Wiley eBooks · doi:10.1002/9781444344110.ch19
Genetic variation in genes involved in Abeta-degradation in Alzheimer disease
Blomqvist, M. '. M. '. (2009) · Figshare
Dorman, H., Meschino, W. S., Allanson, J. E., Blaine, S., Cremin, C., Gibbons, C., Honeywell, C. R., Permaul, J., & Carroll, J. C. (2009) · PubMed Central
Demencia frontotemporal asociada a síndrome de diógenes y dermatitis crónica de difícil control
Flores, Ó. D., Hernández, M. D. R. E., Zetina, D. J. R., & Alvarado, H. L. G. (2009)
Krzan, F. (2014) · The Journal of Neurobehavioral Sciences · doi:10.5455/jnbs.1395921963
“…OF NEUROBEHAVIORAL SCIENCES VOLUME 1 / NUMBER 2 / JULY 2014 begin before the age of 60 are emerging as a result of a genetic mutation which is called the Apolipoprotein (ApoE) ε4 allele: a genetic risk factor for AD (Bertram and Tanzi, 2005; Teter et al., 2002; Farrer et al,. 1997; Blacker, 1997).”
BackgroundIs AD a homogeneous nosologic entity? Yes
Martínez‐Martín, P. (2013) · Journal of Neural Transmission · doi:10.1007/s00702-013-1059-0
“On the contrary, the increased production of Ab42 in the setting of the APP and presenilin mutations causing familial AD (Bertram and Tanzi 2005) and the strong correlation between amyloid b and brain atrophy”
Genetic predisposition in dementia
Yamagata, H. D. (2010) · Nippon Ronen Igakkai Zasshi Japanese Journal of Geriatrics · doi:10.3143/geriatrics.47.41
The Search for Disease-Modifying Drugs for Neurodegenerative Disorders
Lenzken, S. C., Racchi, M., Lucchelli, A., & Govoni, S. M. (2005) · Future Neurology · doi:10.2217/14796708.1.1.87
“b) R ec ru iti ng p at ie nt s [5 3, 10 1]”
BackgroundDrosophila Model of Alzheimer’s Amyloidosis
Iijima, K., Iijima‐Ando, K., & Zhong, Y. (2009) · Springer eBooks · doi:10.1007/978-0-387-76727-7_14
Ramanan, V. K. (2014) · IUScholarWorks (Indiana University) · doi:10.7912/c2/1951
Ramanan, V. K., & Saykin, A. J. (2013)
A HYBRID APPROACH FOR TRANSLATIONAL RESEARCH
Webster, Y. (2010) · IUScholarWorks (Indiana University) · doi:10.7912/c2/906
Modeling Movement Disorders in Parkinson's Disease using Computational Intelligence
Lacy, S. (2015) · White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York) · Cited by 2
Webster, Y., Dow, E. R., & Palakal, M. J. (2011) · Advances in bioinformatics and biomedical engineering book series · doi:10.4018/978-1-61350-435-2.ch011
Executive Functioning in Individuals with Parkinson Disease and Normal Adults
Faris, M., & Parveen, S. (2015)
Jeppsson, F. (2016) · DiVA (Stockholm University)
Is AD a homogeneous nosologic entity? Yes
Wien, S.-V. (2013)
Lana, D. (2016) · Premio Tesi dottorato/Premio Tesi di dottorato · doi:10.36253/978-88-6655-941-2
Understanding Acetylcholinesterase Inhibitors: Computational Modeling Approaches
Nascimento, É. C. M. (2017) · doi:10.6035/14114.2017.415600
Possibilités actuelles et implications des analyses génétiques du point de vue du clinicien
Salili, A. Y. (2006) · Forum Médical Suisse ‒ Swiss Medical Forum · doi:10.4414/fms.2006.05788
Inherited Neurodegenerative Disorders
Sumathipala, D., & Dissanayake, V. H. W. (2018) · Springer eBooks · doi:10.1007/978-981-13-0944-1_7
Ho, R. (2018) · Scholarship@Western (Western University)
Quantification of Protein Aggregates Using Bimolecular Fluorescence Complementation
Prasad, V., & Voigt, A. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8820-4_11
Natural and Synthetic GHSR1a Agonists as Neuroprotective Agents in Models of Parkinson's disease
Rees, D. J. (2017) · Cronfa (Swansea University) · doi:10.23889/suthesis.40946
Topinka, J., Závodná, T., Rössnerová, A., & Rössner, P. (2020) · NANOCOM ... · doi:10.37904/nanocon.2019.8658
“Common symptoms of all neurodegenerative diseases are cognitive function decline (dementia) and motion problems (ataxia) [6].”
BackgroundSalivary Biomarkers in Neurologic Diseases
Zian, Z., & Bouhoudan, A. (2020) · Springer eBooks · doi:10.1007/978-3-030-37681-9_7
Aluri, K. C. (2020) · Digital Repository Service (Northeastern University) · doi:10.17760/d20361345
Brookhouser, N. (2020) · UA Campus Repository (The University of Arizona)
Nose-to-Brain Drug Delivery Enabled by Nanocarriers
Warnken, Z. N., Lu, Y., Smyth, H. D. C., & Williams, R. O. (2020) · Neuromethods · doi:10.1007/978-1-0716-0838-8_8
Shahnawaz, M., & Soto, C. A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-816475-4.00020-3 · Cited by 1
Engineered Biomaterials for Human Neural Stem Cell Applications
Ma, W. (2019) · TUScholarShare (Temple University)
EVALUATING NOVEL THERAPIES FOR NEURODEGENERATIVE DISEASES USING DROSOPHILA MODELS
Williams, H. (2020) · UA Campus Repository (The University of Arizona)
Functional activation during the stroop task in normal older adults & MCI
Puente, A. N. (2012)
Metadata
- Authors
- Bertram, L.
- Affiliations
- Harvard University (US)
- Corresponding author
- Bertram, L.
- ORCID
- Bertram, L.
- Venue
- Journal of Clinical Investigation
- Published
- 2005-06-01
- Volume
- 115
- Issue
- 6
- Pages
- 1449-1457
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC1137006
- OpenAlex
- W2110054485
- Cited by
- 680
- References
- 106
- Citations by year
- 2026: 17 · 2025: 29 · 2024: 40 · 2023: 48 · 2022: 48 · 2021: 40 · 2020: 44 · 2019: 37 · 2018: 46 · 2017: 41 · 2016: 36 · 2015: 20 · 2014: 25 · 2013: 25 · 2012: 34
- FWCI
- 2.89
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Alzheimer's Association
- Massachusetts General Hospital
- National Alliance for Research on Schizophrenia and Depression
- Deutsche Forschungsgemeinschaft
- National Institute on Aging
- National Institute of Mental Health
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Keywords
- neurodegenerative diseases, genetic epidemiology, Alzheimer's disease, Parkinson's disease, dementia with Lewy bodies, frontotemporal dementia, amyotrophic lateral sclerosis, Huntington's disease, prion disease, common disease-common variant hypothesis, complex disease genetics, familial aggregation, genetic risk factors, single nucleotide polymorphisms, gene-environment interaction, genetic heterogeneity, pathogenesis, amyloid precursor protein, alpha-synuclein, tau protein
- MeSH terms
- Chromosome Mapping, Nerve Degeneration, Molecular Epidemiology, Neurodegenerative Diseases, Genetic Predisposition to Disease, Physical Chromosome Mapping
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.